Health plan utilization and costs of specialty drugs within 4 chronic conditions

Journal of Managed Care Pharmacy

Volumn 19, Issue 7, 2013, Pages 542-548

  Gleason, Patrick P ^a   Alexander, G Caleb ^b   Starner, Catherine I ^a   Ritter, Stephen T ^c   Van Houten, Holly K ^d   Gunderson, Brent W ^a   Shah, Nilay D ^d  

^a Prime Therapeutics LLC   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c Blue Cross Blue Shield of Minnesota   (United States)

^d MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETANERCEPT; GLATIRAMER; INFLIXIMAB;

ADULT; ARTICLE; DRUG COST; DRUG USE; DRUG UTILIZATION; ENTERITIS; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MANAGED CARE; MULTIPLE SCLEROSIS; PHARMACY; PREVALENCE; PSORIASIS; RHEUMATOID ARTHRITIS;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; CHRONIC DISEASE; DELIVERY OF HEALTH CARE; DRUG COSTS; DRUG UTILIZATION; FEMALE; HEALTH PLANNING; HUMANS; INFANT; INFANT, NEWBORN; INSURANCE CLAIM REVIEW; INSURANCE, PHARMACEUTICAL SERVICES; MALE; MIDDLE AGED; PHARMACIES; YOUNG ADULT;

EID: 84884131832     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2013.19.7.542     Document Type: Article

References (19)

1. Sullivan SD. The promise of specialty drugs: are they worth the price? J Manag Care Pharm. 2008;14(4 Suppl):S3-S6. Avaiable at: http://www.amcp.org/data/jmcp/JMCPSupp_S3-S6.pdf.
2. Johnson S, Gunderson B, Bowen KL, Starner CI, Gleason PP. Specialty drugs are forecasted to be 50% of all drug expenditures in 2018 [abstract]. J Manag Care Pharm. 2013;19(2):187. Available at: http://www.amcp.org/WorkArea/DownloadAsset.aspx?id=16216.
3. IMS Insitute for Healthcare Informatics. Healthcare spending among privately insured individuals under age 65. February 2012. Available at: http://www.imshealth.com/deployedfiles/ims/Global/Content/Insights/IMS%20 Institute%20for%20Healthcare%20Informatics/Healthcare%20Spending/IHII_Spending_Report.pdf. Accessed May 24, 2013.
4. Prime Therapeutics. 2012 drug trend insights. Available at: http://www. primetherapeutics.com/pdf/2012PrimeDrugTrendInsights.pdf. Accessed May 24, 2013.
5. Stern D. Benefit design innovations to manage specialty drugs. J Manag Care Pharm. 2008;14(4 Suppl):S12-S16. Available at: http://www.amcp.org/data/jmcp/JMCPSupp_S12-S16.pdf.
6. Goldman DP, Joyce GF, Lawless G, Crown WH, Willey V. Benefit design and specialty drug use. Health Aff (Millwood). 2006;25(5):1319-31.
7. Tu HT, Samuel DR. Limited options to manage specialty drug spending. Center for Studying Health System Change. HSC Research Brief No.April 2012. Available at: http://www.hschange.com/CONTENT/1286/. Accessed May 24, 2013.
8. Larson DB, Johnson LW, Schnell BM, Salisbury SR, Forman HP. National trends in CT use in the emergency department: 1995-2007. Radiology. 2011;258(1):164-73. Available at: http://radiology.rsna.org/content/258/1/164.long. Accessed May 24, 2013.
9. Martin AB, Lassman D, Washington B, Catlin A; National Health Expenditure Accounts Team. Growth in U.S. health spending remained slow in 2010; health share of gross domestic product was unchanged from 2009. Health Aff (Millwood). 2012;31(1):208-19.
10. Pfizer receives big boost as FDA approves rheumatoid arthritis drug. Trefis. November 8, 2012. Available at: http://www.trefis.com/stock/pfe/articles/152986/pfizer-receives-big-boost-as-fda-approves-rheumatoid-arthritisdrug/2012-11-08. Accessed May 24, 2013.
11. Alonso A, Hernan MA. Temporal trends in the incidence of multiple sclerosis: a systematic review. Neurology. 2008;71(2):129-35.
12. Ropper AH. The "poison chair" treatment for multiple sclerosis. N Engl J Med. 2012;367(12):1149-50.
13. Chen YF, Jobapurtra P, Barton P, et al. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol Assess. 2006;10(42):iii-iv, xi-xiii, 1-229. Available at: http://www.hta.ac.uk/execsumm/summ1042.htm. Accessed May 24, 2013.
14. Bejarano V, Quinn M, Conaghan PG, et al. Effect of the early use of antitumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis. Arthritis Rheum. 2008;59(10):1467-74. Available at: http://onlinelibrary.wiley.com/doi/10.1002/art.24106/abstract;jsessionid=E01DC338C89791E31067934F792DB0A0.d03t02. Accessed May 24, 2013.
15. Behm BW, Bickston SJ. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev. 2008;23(1):CD006893. Available at: http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006893/abstract. Accessed May 24, 2013.
16. Baldini CG, Culley EJ. Estimated cost savings associated with the transfer of office-administered specialty pharmaceuticals to a specialty pharmacy provider in a medical injectable drug program. J Manag Care Pharm. 2011;17(1):51-59. Available at: http://www.amcp.org/data/jmcp/51-59.pdf.
17. Motheral BR. Pharmaceutical step-therapy interventions: a critical review of the literature. J Manag Care Pharm. 2011;17(2):143-55. Available at: http://www.amcp.org/JMCP/2011/March/9012/1033.html.
18. Navarro RP, Johnson KA. Opportunities and challenges of specialty pharmaceuticals. J Manag Care Pharm. 2013;19(1):70-71. Available at: http://www.amcp.org/WorkArea/DownloadAsset.aspx?id=16081.
19. Jacobs MS, Johnson KA. Curbing the costly trend: exploring the need for a progressive approach to the management of specialty pharmaceuticals under the medical benefit. Am Health Drug Benefits. 2012;5(5):280-89. Available at: http://www.ahdbonline.com/feature/curbing-costly-trendexploring-need-progressive-approach-management-specialty-pharmaceutical. Accessed May 24, 2013.